Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia Coronavirus COVID-19 (REMAP-CAP-COVID-19) - REMAP-CAP

niversity Medical Center Utrecht0 个研究点目标入组 4,000 人开始时间: 2020年3月27日最近更新: 2020年4月6日

研究概览

暂无简介。

•1. Adult patient admitted to an ICU for acute severe CAP within 48 hours of hospital admission with
•a. symptoms or signs or both that are consistent with lower respiratory tract infection (for example, acute onset of dyspnea, cough, pleuritic chest pain) AND
•b. Radiological evidence of new onset infiltrate of infective origin (in patients with pre-existing radiological changes, evidence of new infiltrate)
•2. Up to 48 hours after ICU admission, receiving organ support with one or more of:
•a. Non-invasive or invasive ventilatory support;
•b. Receiving infusion of vasopressor or inotropes or both
•3. Proven or suspected COVID-19 infection
•Precisions for the French part :
•1.Patients under guardianship or curatorship
•2.Informed written consent of the patient or a legally authorized close relative, or emergency procedure.
•In view of the exceptional and urgent situation, affiliation to a social security scheme will not be a criterion for inclusion.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 2000
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2000

•1.Non COVID-19 pneumonia
•Precisions for the French part :
•1.Patients under guardianship or curatorship
•2.Informed written consent of the patient or a legally authorized close relative, or emergency procedure.
•In view of the exceptional and urgent situation, affiliation to a social security scheme will not be a criterion for inclusion.

发起方